10x Genomics Inc. (TXG)
Market Closed
17 Jul, 20:00
$
43. 74
-0.74
-1.6637%
$
5.42B Market Cap
- P/E Ratio
- Div Yield
2.57M Volume
-2.12 Eps
$ 44.48
Previous Close Want to track TXG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
TXG closed today lower at $43.74, a decrease of -1.6637% from yesterday's close, completing a monthly increase of 13.9063% or $5.34. Over the past 12 months, TXG stock gained 168.179%.
TXG is not paying dividends to its shareholders.
The last earnings report, released on May 14, 2026, exceeded the consensus estimates by 0.28%. On average, the company has surpassed earnings expectations by 0.16%, based on the last three reports.
10x Genomics Inc. has completed 1 stock splits, with the recent split occurring on Jul 17, 2006.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.
Zacks | 1 month ago
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
Seekingalpha | 1 month ago
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seekingalpha | 2 months ago
10x Genomics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 296 | $3,545.82 | $13,465.04 | $9,919.22 | 279.74% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 322 | $6,460.06 | $14,664.68 | $8,204.62 | 127.01% |
| BG Bart Gancher Intech Investment Management LLC | 26,061 | $304,468.29 | $1.19M | $880,785.99 | 289.29% |
 Bridgewater Associates LP Bridgewater Associates LP | 35,101 | $572,497.4 | $1.59M | $1.02M | 177.31% |
 Jeffery Yorg Focus Partners Advisor Solutions LLC | 18,918 | $219,070.44 | $844,972.47 | $625,902.03 | 285.71% |
10x Genomics Inc. (TXG) FAQ
What is the stock price today?
The current price is $43.74.
On which exchange is it traded?
10x Genomics Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is TXG.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 5.42B.
Has 10x Genomics Inc. ever had a stock split?
10x Genomics Inc. had 1 splits and the recent split was on Jul 17, 2006.
10x Genomics Inc. Profile
| Life Sciences Tools & Services Industry | Healthcare Sector | Serge Saxonov CEO | NASDAQ (NGS) Exchange | 88025U109 CUSIP |
| US Country | 1,306 Employees | - Last Dividend | 17 Jul 2006 Last Split | 12 Sep 2019 IPO Date |
Overview
10x Genomics, Inc. is a prominent life science technology company known for its innovative development and commercialization of instruments, consumables, and software aimed at analyzing biological systems. The company's footprint extends across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific regions, catering to a diverse clientele that includes academic, government, biopharmaceutical, biotechnology, and other institutions. Originally named 10X Technologies, Inc., it underwent a rebranding to 10x Genomics, Inc. in November 2014. Since its inception in 2012, 10x Genomics has established its headquarters in Pleasanton, California, positioning itself as a leader in the field of genomics and cellular analysis.
Products and Services
- Chromium Instruments: This product line includes the chromium, chromium connect, and chromium controller instruments. These are cornerstone tools for 10x Genomics, facilitating a range of single cell solutions that enable researchers to delve into the intricacies of gene activity and networks on a cell-by-cell basis. The chromium instruments are complemented by microfluidic chips, slides, reagents, and other essential consumables.
- Single Cell Solutions:
- Single Cell Gene Expression: This solution measures gene activity and networks at the individual cell level, providing detailed insights into cellular functions.
- Single Cell Immune Profiling: Targeted at studying the immune system, this solution offers a detailed look at immune cell interactions and functions.
- Single Cell Assay for Transposase Accessible Chromatin (ATAC): Designed to explore the epigenetic landscape of cells, this solution unveils how the accessibility of chromatin influences gene expression.
- Single Cell Multiome ATAC + Gene Expression: This solution allows for the simultaneous investigation of RNA and chromatin accessibility within a single cell, presenting a comprehensive view of cellular function.
- Visium Platform: The Visium platform represents a revolutionary step in tissue analysis, providing researchers with the ability to understand the spatial positioning of biological analytes within tissues at high resolutions. This is crucial for comprehending the complex interplay between cellular components in various biological and pathological states.
- Xenium Platform: Geared towards in situ analysis, the Xenium platform offers an innovative method for analyzing molecular and cellular biology directly within tissue samples. This approach is pivotal for advancing our understanding of complex biological systems and diseases.
Contact Information
Address: 6230 Stoneridge Mall Road
Phone: 925 401 7300
Website: https://www.10xgenomics.com
